ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
NFE2L2	4780	21228930	Endometrial Serous carcinoma	Up regulation/ Over expression/High expression	Diagnostic Marker	-	-	231 specimens were studied which included benign endo-metrium (n=28); atypical endometrial hyperpla-sia or endometrial intraepithelial neoplasia (n=18); serous endometrial glandular dysplasia (EmGD) (n=20); serous endometrial intraepithelial carcinoma (EIC) (n=25); clear cell EmGD (n=10); clear cell EIC (n=8); endometrioid carcinoma (n=50); serous carcinoma (n=41); clear cell carcinoma (n=15); mucinous carcinoma (n=8); and other malignancies (n=8). Cancers grouped in the other category included those undifferentiated carcinoma (n=3); carcinosarcoma (n=3); squamous cell carcinoma (n=2)	-	-	Department of Pathology; University of Arizona	-	1 (n=1); 2 (n=9); 3 (n=7)	[1] Nrf2 overexpression is closely associated with endometrial neoplasms with serous differentiation. Alteration of Nrf2 expression may represent one of the early molecular events in ESC carcinogenesis and overexpression of Nrf2 may used as a diagnostic marker in surgical pathology. [2] Among the malignant cases; Nrf2 was positive in 28 (68%) of 50 ESCs; which was significantly more than in 3 (6%) of 50 endometrioid carcinomas (p < 0.001) and 2 (13%) of 15 clear cell carcinomas (p = 0.001) and other histologic types of endometrial cancers. Among endometrial precursor lesions; both serous endometrial glandular dysplasia (EmGD; 40%) and serous endometrial intraepithelial carcinoma (EIC; 44%) showed a significantly higher Nrf2 expression than that in atypical endometrial hyperplasia or endometrial intraepithelial neoplasia (0%); clear cell EmGD (10%); and clear cell EIC (25%); respectively.	Nrf2 expression in endometrial serous carcinomas and its precancers	International Journal of Clinical and Experimental Pathology	4(1):85-96	2010